Mast Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mast Therapeutics, Inc.
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
- Drug Delivery
- Other Names / Subsidiaries
- Adventrx Pharmaceuticals, Inc.
- Aires Pharmaceuticals, Inc.
- SynthRx, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.